Comparative Pharmacology
Head-to-head clinical analysis: FLOXIN IN DEXTROSE 5 versus GEMIFLOXACIN MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOXIN IN DEXTROSE 5 versus GEMIFLOXACIN MESYLATE.
FLOXIN IN DEXTROSE 5% vs GEMIFLOXACIN MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and transcription.
400 mg intravenously every 12 hours.
320 mg orally once daily for 7-14 days
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (prolonged in renal impairment, up to 20-30 hours in severe impairment).
Terminal elimination half-life 7–9 hours (mean 8.2 h) in healthy adults; prolonged in renal impairment (e.g., 15–22 h in severe renal impairment).
Primarily renal (approximately 70-90% unchanged drug), with 5-10% biliary/fecal elimination.
Renal: ~61% as unchanged drug, ~7% as glucuronide; Fecal/biliary: ~28% as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic